Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? from mg php Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Ian Krop speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the results from the DESTINY-Breast01 study which investigated the effect of the investigational drug trastuzumab deruxtecan in HER2-positive breast cancer patients who have been pretreated with TDM-1. nnHe outlines the background of this study and describes the use of this agent - which is a HER2-targeted antibody-drug conjugate. nnDr Krop reports the findings from this study, in which patients were treated with
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)